# Senescence-Driven Inflammation and Immune Dynamics in the Progression of Radiation Cystitis

**Authors:** Sabrina Mota, Austin Goodyke, Elijah P. Ward, Rani Mahyoob, Yung-Chun Lee, Sarah N. Bartolone, Alyssa Mularski, Michael B. Chancellor, Bernadette M. M. Zwaans

PMC · DOI: 10.3390/cells15040337 · Cells · 2026-02-13

## TL;DR

This study explores how radiation-induced cell aging and immune changes contribute to bladder inflammation and dysfunction in radiation cystitis.

## Contribution

The study identifies immune and senescence-driven mechanisms during the latent phase of radiation cystitis, previously unanalyzed.

## Key findings

- Latent and chronic phases of RC are marked by distinct inflammatory signaling and cytokine profiles.
- Persistent Cdkn1a (P21) upregulation indicates sustained senescence during RC progression.
- Immune shifts and SASP proteins correlate with bladder dysfunction in chronic RC.

## Abstract

Pelvic radiation therapy is an essential treatment for several pelvic malignancies, but it can lead to radiation cystitis (RC), a severe progressive inflammatory bladder disorder lacking effective diagnosis and therapeutic options. RC evolves through acute, latent, and chronic phases, ultimately resulting in bladder fibrosis, vascular damage, and hematuria. Here, we characterize the molecular and immunological features associated with RC progression using a preclinical mouse model. Building on a prior analysis of the acute and chronic phases, we examined the previously unanalyzed latent phase and integrated transcriptomics, immune cell profiling, inflammatory protein measurements, and bladder function assessments across all stages. Acute radiation injury was marked by the strong activation of apoptotic pathways, whereas latent and chronic phases were dominated by inflammatory signaling with distinct cytokine and chemokine signatures. The persistent upregulation of Cdkn1a (P21) was consistent with sustained senescence-associated signaling, while reductions in IL-27 and shifts in the granulocyte–lymphocyte-enriched immune population during the latent phase were consistent with altered immune regulatory states. At chronic stages, increased SASP-associated proteins and matrix remodeling mediators coincided with bladder functional decline. Together, these findings support a model in which radiation-induced senescence, coupled with immune dysregulation during the latent phase, are coordinated features accompanying inflammation, tissue remodeling, and bladder dysfunction in RC.

## Linked entities

- **Genes:** CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026], CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026]
- **Proteins:** IL27 (interleukin 27)
- **Diseases:** radiation cystitis (MONDO:0004112)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], Il7r (interleukin 7 receptor) [NCBI Gene 16197] {aka CD127, IL-7Ralpha}, Il27 (interleukin 27) [NCBI Gene 246779] {aka IL-27, IL-27-A, IL-27p28, IL27-A, Il30, p28}, Cd44 (CD44 antigen) [NCBI Gene 12505] {aka HERMES, Ly-24, Pgp-1}, Ccl5 (C-C motif chemokine ligand 5) [NCBI Gene 20304] {aka MuRantes, RANTES, SISd, Scya5, TCP228}, Ly6g (lymphocyte antigen 6 family member G) [NCBI Gene 546644] {aka Gr-1, Gr1, Ly-6G}, Ccl2 (C-C motif chemokine ligand 2) [NCBI Gene 20296] {aka HC11, JE, MCAF, MCP-1, MCP1, SMC-CF}, Areg (amphiregulin) [NCBI Gene 11839] {aka AR, Mcub, Sdgf}, Atr (ataxia telangiectasia and Rad3 related) [NCBI Gene 245000], Cxcl10 (C-X-C motif chemokine ligand 10) [NCBI Gene 15945] {aka C7, CRG-2, INP10, IP-10, IP10, Ifi10}, Ccl4 (C-C motif chemokine ligand 4) [NCBI Gene 20303] {aka AT744.1, Act-2, MIP-1B, Mip1b, Scya4}, Il13 (interleukin 13) [NCBI Gene 16163] {aka Il-13}, Icam1 (intercellular adhesion molecule 1) [NCBI Gene 15894] {aka CD54, Icam-1, Ly-47, MALA-2}, Ccl3 (C-C motif chemokine ligand 3) [NCBI Gene 20302] {aka G0S19-1, LD78alpha, MIP-1alpha, MIP1-(a), MIP1-alpha, Mip1a}, Mmp3 (matrix metallopeptidase 3) [NCBI Gene 17392] {aka EMS-2, MMP-3, SL-1, SLN-1, SLN1, STR-1}, Ccl7 (C-C motif chemokine ligand 7) [NCBI Gene 20306] {aka MCP-3, Scya7, fic, marc, mcp3}, Atm (ataxia telangiectasia mutated) [NCBI Gene 11920] {aka C030026E19Rik}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, Cdkn1a (cyclin dependent kinase inhibitor 1A) [NCBI Gene 12575] {aka CAP20, CDKI, CIP1, Cdkn1, P21, SDI1}, Ly6c1 (lymphocyte antigen 6 family member C1) [NCBI Gene 17067] {aka Ly-6C, Ly-6C1, Ly6c}, Ccl12 (C-C motif chemokine ligand 12) [NCBI Gene 20293] {aka MCP-5, Scya12}, Pecam1 (platelet/endothelial cell adhesion molecule 1) [NCBI Gene 18613] {aka Cd31, PECAM-1, Pecam}, Ccl22 (C-C motif chemokine ligand 22) [NCBI Gene 20299] {aka ABCD-1, DCBCK, MDC, Scya22}, Il16 (interleukin 16) [NCBI Gene 16170] {aka mKIAA4048}, Cd3e (CD3 antigen, epsilon polypeptide) [NCBI Gene 12501] {aka CD3, CD3epsilon, T3e}, Ccl11 (C-C motif chemokine ligand 11) [NCBI Gene 20292] {aka Scya11, eotaxin}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Ccl8 (C-C motif chemokine ligand 8) [NCBI Gene 20307] {aka 1810063B20Rik, HC14, MCP-2, Mcp2, Scya8}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Cxcl1 (C-X-C motif chemokine ligand 1) [NCBI Gene 14825] {aka Fsp, Gro1, KC, Mgsa, N51, Scyb1}, Cd19 (CD19 antigen) [NCBI Gene 12478], Kit (Kit proto-oncogene receptor tyrosine kinase) [NCBI Gene 16590] {aka Bs, CD117, Fdc, Gsfsco1, Gsfsco5, Gsfsow3}
- **Diseases:** hemorrhagic (MESH:D006470), dysuria (MESH:D053159), bladder complication (MESH:D001745), Cystitis (MESH:D003556), inflammatory dysregulation (MESH:D021081), vascular fragility (MESH:D005600), mitochondrial dysfunction (MESH:D028361), hematuria (MESH:D006417), bladder fibrosis (MESH:D005355), pelvic malignancies (MESH:D010386), injury to (MESH:D014947), Inflammation (MESH:D007249), malignancies (MESH:D009369), RC Disease (MESH:D011832), chronic (MESH:D002908), urological diseases (MESH:D014570), immune dysregulation (OMIM:614878), underactive bladder (MESH:D000077295), prostate, cervical or colorectal cancer (MESH:D015179), age (MESH:D019588), vascular damage (MESH:D057772)
- **Chemicals:** isoflurane (MESH:D007530), 7-AAD (MESH:C025942), nitrogen (MESH:D009584), ROS (MESH:D017382), PRT (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12939091/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939091/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12939091/full.md

---
Source: https://tomesphere.com/paper/PMC12939091